Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Sarepta Therapeutics has a consensus “Hold” rating from 20 brokerages: nine recommend buying, six rate it a hold, and five recommend selling. The average 12-month price target is $25.06.
• Recent analyst views were mixed, with Wolfe Research upgrading the stock to “outperform” and HC Wainwright reaffirming “buy,” while Piper Sandler cut its target to $20 and Wall Street Zen downgraded the shares to “hold.”
• Sarepta reported quarterly revenue of $401.25 million and adjusted earnings of $0.64 per share, beating estimates, though revenue fell 34.3% year over year. The stock opened at $18.79, within a 12-month range of $14.68 to $25.32.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been assigned an average recommendation of "Hold" from the twenty brokerages that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $25.0588.

SRPT has been the subject of a number of recent research reports. Weiss Ratings downgraded shares of Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a research note on Wednesday. HC Wainwright reaffirmed a "buy" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Wolfe Research upgraded Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, July 9th. Wall Street Zen cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Piper Sandler decreased their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research note on Thursday, July 9th.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $18.79 on Monday. The company's fifty day simple moving average is $17.42 and its 200-day simple moving average is $18.28. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The firm has a market cap of $1.98 billion, a PE ratio of -6.48, a P/E/G ratio of 0.28 and a beta of 0.24. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. During the same quarter last year, the firm earned $2.02 earnings per share. The firm's revenue for the quarter was down 34.3% compared to the same quarter last year. Equities research analysts expect that Sarepta Therapeutics will post 3.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its position in Sarepta Therapeutics by 214.2% during the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company's stock worth $344,000 after acquiring an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at $224,000. Guggenheim Capital LLC grew its position in shares of Sarepta Therapeutics by 33.5% in the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company's stock valued at $783,000 after acquiring an additional 11,497 shares during the period. First Trust Advisors LP grew its position in shares of Sarepta Therapeutics by 59.2% in the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company's stock valued at $10,731,000 after acquiring an additional 233,391 shares during the period. Finally, California Public Employees Retirement System increased its stake in shares of Sarepta Therapeutics by 7.1% during the 2nd quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company's stock worth $1,972,000 after purchasing an additional 7,665 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source